Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. From the corporate jets of Teterboro Airport to ...

After months of threats, President Trump eased up pressure on drugmakers late last year. That’s all it took for investors to notice that the beaten-down sector was actually growing just fine. Talk of ...

Major drugmakers are set to raise the price of hundreds of drugs in the U.S., despite pressure from the Trump administration to cut prices. The data shows the number of price increases for 2026 is up ...

Back in February, newly-confirmed Secretary of Health and & Human Services (HHS) Robert F. Kennedy Jr. promised to reverse decades of industry capture of the public health agencies. Yet, recent moves ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year. Aktis saw the likes of Bristol Myers ...

Harvest Portfolios Group Inc. (“Harvest”) declares the monthly cash distribution payable for Big Pharma Split Corp. of $0.1031 for each class A share (PRM:TSX) for the month ending December 31, 2025.

The current generation of deals, which is likely to involve AbbVie (NYSE: ABBV), Merck & Co Inc (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), and Gilead Sciences Inc (NYSE: GILD), is focused on ...

“Affordability” is the watchword in American politics today. Inflation is squeezing families, but nothing hits harder than the cost of trying to stay alive. Yet as patients weigh whether they can ...

Mike Feuz is an economic consultant by day and a research associate for the think tank Free the People by night. He has a master’s degree in economics from George Mason University. For years, ...

For pharmaceutical firms, watching the lucrative patents on their top-selling drugs expire has long been part of the business cycle. There’s enormous pressure to find ways of covering the shortfall.